Clinical trials
Relapsed or Refractory Peripheral T Cell Lymphoma clinical trials
Below are recruiting relapsed or refractory peripheral t cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,702 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04239157RecruitingPhase 2
Canakinumab shot for lower-risk MDS and related blood disorders
This trial tests canakinumab, a medication that blocks inflammation, given as a skin (subcutaneous) injection. It is for adults with lower-risk myelodysplastic syndromes (MDS) or a related condition (chronic myelomonocytic leukemia or CCUS) to see if it can improve blood counts and reduce problems like anemia or transfusion needs.
Houston, TexasAges 18 years+ - NCT04012905RecruitingPhase 3
Compare two steroid taper schedules for giant cell arteritis
This Phase 3 study compares how two standard steroid dose-reduction (tapering) schedules work for people with giant cell arteritis. It aims to see which taper approach controls the disease while reducing problems from long-term steroid use.
CaenAges 50 years+ - NCT03739814RecruitingPhase 2
Test inotuzumab, blinatumomab, and possibly ponatinib for CD22 ALL
This Phase 2 study tests a combination of medicines (inotuzumab ozogamicin and blinatumomab), with or without ponatinib, for people with CD22-positive B-cell acute lymphoblastic leukemia (ALL). It aims to improve remission and control leukemia cells, including in the bone marrow.
Birmingham, AlabamaAges 18 years+ - NCT03721068RecruitingPhase 1
CAR T-cell treatment for hard-to-treat childhood tumors
This Phase 1 study tests an experimental CAR T-cell treatment that targets GD2, with added immune-boosting and safety features, for children with relapsed or refractory neuroblastoma or osteosarcoma. It’s designed to see if the treatment is safe and can shrink these cancers when standard therapy hasn’t worked.
Atlanta, GeorgiaAges 1.5 years+ - NCT03741426RecruitingPhase 2
New drug combinations for kidney cancer before surgery
This trial tests new drug combinations for kidney cancer that is removable by surgery but may have spread. The goal is to see if these treatments can shrink tumors before surgery and improve outcomes.
Cambridge, EnglandAges 18 years+ - NCT03113643RecruitingPhase 1
SL-401 with standard drugs for hard-to-treat blood cancers
This Phase 1 study tests SL-401, given with azacitidine and sometimes venetoclax, to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN). It aims to find a safe dose and see whether the combination can improve blood cancer control.
Duarte, CaliforniaAges 18 years+ - NCT03000244Recruiting
Long-term follow-up after stem cell or gene therapy
This study checks how people do long-term after stem cell transplant, cellular therapy, or gene therapy. It may help doctors track longer-term health effects and recovery and improve future care.
Bethesda, MarylandAges 4–120 - NCT02582697RecruitingPhase 3
Faster vs standard chemotherapy for spreading germ cell tumors
This Phase 3 trial compares a faster chemotherapy approach versus the standard schedule for people with intermediate- or poor-risk metastatic germ cell tumors. The goal is to see which schedule works better and is safer enough to use as initial treatment.
Downey, CaliforniaAges 11–50 - NCT02443831RecruitingPhase 1
CAR T-cell immunotherapy for high-risk childhood leukemia
This early-phase trial tests CAR T-cells made to attack leukemia cells with specific markers (CD19 and CD22). It may help people with difficult-to-treat, relapsed, or high-risk acute lymphoblastic leukemia (ALL), especially when standard treatments haven’t worked well.
LondonAges Up to 24 years - NCT02048332RecruitingPhase 1/Phase 2
Donor immune cells for preventing infections after stem cell transplant
This trial studies donor-made immune cells (T-cells) given after a stem cell transplant to help your body fight infections. It aims to test how safe the treatment is and whether it supports the immune system in the months after transplant.
Akron, OhioAges 4 weeks+ - NCT07870265Recruiting
Blood test for detecting BRAF mutation in melanoma
This trial tests a new blood test to detect a specific gene change (BRAF V600E) in melanoma that has come back. The test uses a technology called CRISPR to find the mutation in a simple blood draw, which could help guide treatment without needing a tissue biopsy.
Brno, BrnoAges 18 years+ - NCT06676059Recruiting
Substance use monitoring study with a smartphone app
This study uses a smartphone app and daily surveys to track alcohol or drug use. It aims to create a database for future research on addiction patterns and recovery.
Baltimore, MarylandAges 18–120 - NCT07607327Enrolling by invitation
Blood test to predict relapse after stem cell transplant
This study is testing a blood test called AlloHeme that may help doctors predict whether your blood cancer will come back after a stem cell transplant. Joining this study could help you and your doctor monitor your recovery more closely.
Brisbane, CaliforniaAges 18 years+ - NCT06904066RecruitingPhase 1
Personalized T cell therapy for blood cancers
This trial tests a treatment that takes your own immune cells, modifies them to attack cancer cells, and gives them back to you. It is for people with certain blood cancers who have specific gene changes.
Bethesda, MarylandAges 18–120 - NCT07200102RecruitingPhase 1
Selinexor after CAR-T for high-risk multiple myeloma
This study tests whether taking selinexor after CAR-T cell therapy can help keep multiple myeloma from coming back. It is for people whose myeloma is high-risk or still has signs of disease after CAR-T.
St Louis, MissouriAges 18 years+ - NCT07109219RecruitingPhase 1/Phase 2
Study of AZD4512 alone or with other drugs for leukemia
This study tests a new medicine called AZD4512, given alone or with other cancer drugs, for people whose B-cell acute lymphoblastic leukemia (a type of blood cancer) has come back or not improved after treatment. The goal is to see if it can help control the disease.
Duarte, CaliforniaAges 12 years+ - NCT02918188RecruitingPhase 2
Hydrogen therapy for steroid-resistant graft-versus-host disease
This Phase 2 study tests whether hydrogen therapy can improve symptoms in people with chronic graft-versus-host disease (cGVHD) who cannot tolerate steroid treatment. If steroids aren’t working or can’t be used, this trial may offer an alternative approach to help control the illness.
Beijing, Beijing MunicipalityAges Up to 65 years - NCT04771507RecruitingPhase 1/Phase 2
Testing intermittent ibrutinib for advanced chronic lymphocytic leukemia
This trial studies whether taking ibrutinib in a less continuous (“intermittent”) schedule can keep your chronic lymphocytic leukemia (CLL) under control. It’s for people who have already received ibrutinib for at least 6 months and had a good early response, aiming to reduce treatment intensity while tracking safety and cancer control.
TrondheimAges 18 years+ - NCT05124964Recruiting
Quality of life study for newly diagnosed brain germ cell tumors
This study looks at how life quality changes in children and young adults after a new diagnosis of a brain germ cell tumor. It may help doctors understand which supports improve day-to-day well-being.
BeijingAges 3–30 - NCT04996121RecruitingPhase 1/Phase 2
Drug for tumors with NTRK or ROS1 gene fusions
This trial studies an investigational pill (XZP-5955) for solid tumors that have specific gene changes: NTRK or ROS1 fusions. It is meant for people whose cancer is advanced or has spread, and who may not have good standard treatment options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05682131RecruitingPhase 4
Study for children with certain relapsed leukemia
This trial looks at treatment for children whose leukemia has come back for the first time. It focuses on a specific type of leukemia and risk level to see whether the approach improves outcomes.
Guangzhou, GuangdongAges 1–14 - NCT05554068RecruitingPhase 2
Testing the shingles vaccine response after bone marrow transplant
This Phase 2 study looks at how well the shingles vaccine works in people who had an allogeneic (donor) stem cell transplant. It aims to measure the body’s immune response to the vaccine and check that it’s safe in this recovery period.
Maywood, IllinoisAges Any age - NCT05861505RecruitingPhase 3
Treatment for new liver spread from colon cancer recurrence
This Phase 3 trial studies a treatment approach for people whose colorectal cancer has come back in the liver within 12 months and can be treated with local procedures. It aims to see whether the study treatment can improve outcomes compared with standard care for people with a limited number of liver tumors.
AmsterdamAges 18 years+ - NCT04758000RecruitingPhase 2
Metformin after bone cancer treatment to prevent relapse
This Phase 2 study tests whether taking metformin after surgery and chemotherapy can reduce the risk of bone cancer coming back in people at high risk of relapse. You may be eligible if you have osteosarcoma or Ewing sarcoma that is not currently spread and you meet specific lab and health criteria.
BolognaAges 14 years+
Hear when a new Relapsed or Refractory Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory peripheral t cell lymphoma?
- Yes. Clin2 currently lists 1,702 recruiting relapsed or refractory peripheral t cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory peripheral t cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory peripheral t cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory Peripheral T Cell Lymphoma
- Relapsed/Refractory B-cell Lymphoma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed Peripheral T-Cell Lymphoma
- Relapsed or Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed/Refractory Large B-Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.